Treatment of patients with fibromyalgia syndrome using the Rességuier and Qi Gong methods

Rességuier and Qi Gong methods applied sequentially in patients with fibromyalgia syndrome: a randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN99342127

Enrollment

Registered

2012-02-17

Start date

2011-04-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia syndrome Musculoskeletal Diseases Fibromyalgia

Interventions

30 FMS patients are recruited and randomly assigned to the Group A and Group B. Group A: 15 patients, treated firstly with RM for 7 weeks (two sessions per week in the first 3 weeks and once per week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis of fibromyalgia syndrome according to the American College of Rheumatology (ACR) criteria

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
The following items are assessed at baseline (T0), at end of the first (week 7: T1) and the second treatment (week 15: T2) and after 9 weeks of follow-up (week 27: FU): 1. Pain assessed by regional pain scale (RPS) 2. Disability assessed by Fibromyalgia Impact Questionnarie (FIQ) and Health Assessment Questionnaire (HAQ)	—

Secondary

Measure	Time frame
The following items are assessed at baseline (T0), at end of the first (week 7: T1) and the second treatment (week 15: T2) and after 9 weeks of follow-up (week 27: FU): 1. Tenderness in specific FMS sites (by the tender points evaluation) 2. Quality of life by Medical Outcomes Survey Short Form 36 (SF-36) 3. Anxiety and Depression by Hospital Anxiety and Depression Scale (HADS), with subscales for anxiety (HADS-a) and depression (HADS-d) 4. Quality of sleep by a number rating scale 0?10 (NRS- 0?10)	—

Measure

Time frame

The following items are assessed at baseline (T0), at end of the first (week 7: T1) and the second treatment (week 15: T2) and after 9 weeks of follow-up (week 27: FU): 1. Tenderness in specific FMS sites (by the tender points evaluation) 2. Quality of life by Medical Outcomes Survey Short Form 36 (SF-36) 3. Anxiety and Depression by Hospital Anxiety and Depression Scale (HADS), with subscales for anxiety (HADS-a) and depression (HADS-d) 4. Quality of sleep by a number rating scale 0?10 (NRS- 0?10)

—

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026